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Non-standard Abbreviations: 
2-DE Two-dimensional electrophoresis 
4E-BP1 4E-binding protein 1 
Acadl Acyl-Coenzyme A dehydrogenase, long-chain 
ACO2 Aconitase 2 
AHA L-azidohomoalanine 
ALDOA Aldolase A 
ARVC Adult rat ventricular cardiomyocytes 
CDS Coding DNA sequence 
CH Cardiac hypertrophy 
FDR False discovery rate 
hnRNPs Heterogeneous nuclear RNA-binding proteins 
HSP60 Heat shock 60kDa protein 1 
IGF1 Insulin-like growth factor 1 
Lmod Leiomodin 
MDH2 Malate dehydrogenase 2 
mTORC1 mammalian target of rapamycin complex 1 
NRAP Nebulin-related anchoring protein 
PE Phenylephrine 
QuaNCAT 
pSILAC 
Quantitative Non-Canonical Amino acid Tagging 
pulsed stable isotope-labeling with amino acids in cell culture 
PTBP1 Polypyrimidine tract-binding protein 1 
RPs Ribosomal proteins 
S6Ks S6 kinases 
TAC Transverse aortic constriction 
TOP Terminal oligopyrimidine tract 
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SUMMARY 
Cardiomyocytes undergo growth and remodeling in response to specific pathological 
or physiological conditions. Pathological myocardial growth is a risk factor for cardiac 
failure to which faster protein synthesis is a major driving element. We aimed to 
quantify the rapid effects of different pro-hypertrophic stimuli on the synthesis of 
specific proteins in ARVC and to determine whether such effects are due to 
alterations on mRNA abundance or the translation of specific mRNAs. 
Cardiomyocytes have very low rates of protein synthesis, posing a challenging 
problem in terms of studying changes in the synthesis of specific proteins, which also 
applies to other non-dividing primary cells. To address this, an optimized QuaNCAT 
LC/MS method was used to selectively quantify newly synthesized proteins in such 
cells. The study showed both classical (phenylephrine; PE) and more recent (insulin) 
pathological cardiac hypertrophic agents increased the synthesis of proteins involved 
in glycolysis, the Krebs cycle / beta-oxidation, and sarcomeric components. 
However, insulin increased synthesis of many metabolic enzymes to a greater extent 
than PE. Using a novel validation method, we confirmed that synthesis of selected 
candidates is indeed up-regulated by PE and insulin. Synthesis of all proteins 
studied was upregulated by signaling through mTORC1 without changes in their 
mRNA levels, showing the key importance of translational control in the rapid effects 
of hypertrophic stimuli. Expression of PKM2 was upregulated in rat hearts following 
TAC. This isoform possesses specific regulatory properties that may be involved in 
metabolic remodeling and as a novel candidate biomarker. Levels of translation 
factor eEF1 also increased during TAC, likely contributing to faster cell mass 
accumulation. Interestingly, PKM2 and eEF1 were not up-regulated in pregnancy or 
exercise induced CH, suggesting them as pathological CH specific markers. The 
study methods may be of utility to the examination of protein synthesis in primary 
cells. 
 
Keywords: 
Cardiac hypertrophy, pSILAC, AHA labeling, QuaNCAT, mTORC1, PKM2. 
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INTRODUCTION 
Cardiac hypertrophy (CH) describes the enlargement of the myocardium and 
can be classified as either the ‘physiological’ or ‘pathological’ types. The latter is 
usually caused by conditions such as chronic hypertension, and is initially an 
adaptive response to help the heart to maintain normal function. However, sustained 
pressure overload leads to chronic hypertrophy and myocardial dysfunction. Indeed, 
pathological cardiac hypertrophy usually progresses into heart failure and is a major 
cause of death in young adults in developed countries. In contrast, physiological 
hypertrophy, as caused by pregnancy or exercise, is beneficial (1-4).  
The differences between pathological and physiological hypertrophy are 
profound; for example, fetal genes such as natriuretic peptides A and B are 
upregulated in pathological, but not physiological, hypertrophy (5). In pathological 
hypertrophy, cardiac function usually becomes impaired, whereas in physiological 
hypertrophy, it is usually preserved or even enhanced. Metabolic remodeling is 
another significant change during cardiac hypertrophy. In pathological hypertrophy, 
fatty acid β-oxidation decreases whereas glucose utilization increases. In contrast, 
both fatty acid oxidation and glucose oxidation are upregulated in physiological 
hypertrophy. Pathological hypertrophy is also associated with mitochondrial 
dysfunction, fibrosis and cell apoptosis; in physiological hypertrophy mitochondrial 
biogenesis is upregulated, and neither fibrosis nor apoptosis are observed. 
Furthermore, distinct signaling pathways are activated in different types of 
hypertrophy: in physiological hypertrophy, insulin-like growth factor (IGF) 1 activates 
signaling via phosphoinositide 3-kinase signaling while well-established inducers of 
pathological hypertrophy, such as the α1-adrenergic agonist phenylephrine (PE), 
which stimulates signaling through Gαq and the classical mitogen-activated protein 
kinase kinase/extracellular signal-regulated kinase (ERK) pathway (6). In both cases, 
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mTORC1 (mammalian target of rapamycin complex 1) signaling is activated. Insulin 
activates the IGF-1 signaling pathway at the supraphysiological concentration of 100 
nmol/L, so was believed to promote the physiological hypertrophic growth of 
cardiomyocytes at this concentration similarly to IGF-1 (7). However, a recent study 
showed that insulin signaling actually contributes to the development of pathological 
cardiac hypertrophy (8). The relationship between pathological CH induced by α1-
adrenergic stimulation or by insulin has not previously been explored, and doing this 
is one goal of the present study.  
Both pathological and physiological types of CH are a consequence of 
cardiomyocyte growth. As most of a cell’s dry mass is protein, elevated protein 
synthesis plays a central role in cell growth (9), and mTORC1 is a key positive 
regulator of protein synthesis and cell growth. Activation of mTORC1 was observed 
in exercise-induced (10) cardiac hypertrophy. Similarly, in TAC mice, mTORC1 is 
initially rapidly activated, but subsequently inactivated. Indeed, administration of the 
mTORC1-specific inhibitor rapamycin prior to or after TAC can attenuate or reverse 
TAC-induced hypertrophy and heart dysfunction in mice (11, 12). Given the distinct 
signaling pathways activated α-adrenergic stimulation and insulin in ARVC, and their 
roles in cardiac hypertrophy, it was therefore important to compare the impact on the 
synthesis of specific proteins in ARVC. 
mTORC1 plays important roles in regulating protein synthesis in isolated adult 
rat ventricular cardiomyocytes (ARVC). Indeed, activating mTORC1 by over-
expressing a small GTPase, Rheb, which positively regulates mTORC1 (13), is 
sufficient to drive rapid and marked growth of ARVC (14). PE substantially enhances 
global protein synthesis and ARVC growth which is largely blocked by rapamycin 
(14), again indicating that mTORC1 signaling is important for CH. Insulin also 
stimulates protein synthesis in an mTORC1-dependent manner in ARVC (15). 
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This study aims to address several key questions: which specific proteins’ synthesis 
is increased in response to different hypertrophic stimuli? Are those proteins also 
altered in pathological and physiological animal models? Are changes in the 
synthesis of specific proteins exerted at the level of transcription or translation? Does 
mTORC1 signaling play a role in regulating the translation of specific mRNAs?  
To address these questions, we optimized a recently developed method 
wherein stable-isotope labeled amino acids are used to tag newly-synthesized 
proteins (pulsed SILAC; pSILAC). Such a pSILAC approach was used to study the 
regulation of protein accumulation rates by mTOR signaling in HeLa cells (16), a 
rapidly-dividing cancer cell line, which synthesises proteins at a much higher rate 
than primary cells such as ARVC. We subsequently improved the pSILAC approach 
to enhance its selectivity and sensitivity for the analysis of newly synthesized 
proteins by combining it with azidohomoalanine (AHA) labeling/click-chemistry and 
subsequent bottom-up LC-MS proteomic analysis (Figure 1) (17). During incubation 
in cell culture, AHA (an analog of methionine) becomes incorporated into, and 
covalently tags, newly-synthesized proteins. The resulting azide-derivatized proteins 
can then be selectively coupled and enriched to biotin-alkyne beads for visualization 
using fluorescently-labeled streptavidin. Alternatively, the azide-derivatized proteins 
are selectively isolated and enriched with alkyne-functionalized agarose beads and 
subjected to trypsin proteolysis followed by liquid chromatography - mass 
spectrometry (LC-MS/MS). The collective analytical attributes of this proteomics 
approach, referred to as Quantitative Non-Canonical Amino acid Tagging 
(QuaNCAT), permits the sensitive and selective measurement of the synthesis rates 
of specific proteins in cells (18, 19). Other quantitative proteomic approaches that 
rely on the use of label-free and isobaric stable isotope labeling to examine the 
differential expression of proteins in hypertrophic or diseased heart (20-22) only 
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capture relative steady-state protein concentration levels rather than assessing rates 
of de novo synthesis. They are thus unsuitable for addressing the aims of the current 
study. We have optimized and applied the QuaNCAT approach to measure the 
regulated synthesis of specific proteins in ARVC cells observed to occur at a very 
low rate.  
Our results revealed several key new features in the response of 
cardiomyocytes to hypertrophic stimuli. These include: (i) both insulin and PE 
increased the protein synthesis rate to a similar set of proteins. Additionally, marked 
differences were observed in the patterns of induction of metabolic enzymes and 
other proteins in response to PE and insulin; (ii) increased synthesis of pyruvate 
kinase M2, a protein involved in anabolic remodelling of cellular metabolism, which 
may also represent a new early marker for cardiac hypertrophy; (iii) the widespread 
importance of increased translation (rather than transcription) in the rapid effects of 
hypertrophic agents and (iv) a key role for mTORC1 signaling in the effects of 
hypertrophic agents of the translation of specific mRNAs, including many mRNAs 
which are not members of the subset of TOP (terminal oligo-pyrimidine) mRNAs 
which are translationally regulated by mTORC1.  
 
 
EXPERIMENTAL PROCEDURES 
Experimental Design and Statistical Rationale 
ARVCs derived from wild-type Sprague–Dawley male rats were treated with 
phenylephrine (10 µmol/L), insulin (100 nmol/L) and rapamycin (100 nmol/L). AHA-
pSILAC was combined with mass spectrometry to identify newly synthesized 
proteins as a result of each treatment. Replicate experiments were performed, three 
in the case of insulin and four for phenylephrine. 
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Identified proteins were validated in ARVCs using two similar but independent 
methods. We determined the total mRNA levels of selected candidate proteins, to 
examine whether increased synthesis of these proteins reflects increased translation 
of their mRNAs or increased mRNA levels. 
To test the role of mTORC1 signaling in regulating the synthesis of specific proteins 
in ARVCs, we repeated the AHA-pSILAC labeling experiments using ARVCs that 
were treated with PE or insulin in the presence of the mTORC1 inhibitor rapamycin. 
Finally, key proteomic results were studied using in vivo rodent models of pathologic 
and physiologic cardiac hypertrophy. Data from independent experimental replicates 
were analysed using Student’s t-test, Significance was set to p = 0.05. 
 
Rats 
Animals used for isolating ARVC were wild-type Sprague–Dawley male rats from 
Charles River, UK. Animals were reared and sacrificed in line with the United 
Kingdom Animals (Scientific Procedures) Act, 1986. The method of sacrifice 
employed here was cervical dislocation according to the UK Home Office regulations 
Schedule 1. Animals used in the TAC study were as described earlier (23). 
 
Isolation of adult rat ventricular cardiomyocytes 
Isolation and maintenance of adult rat ventricular cardiomyocytes were described 
earlier (15, 24). ARVC were treated with following compounds at the indicated 
concentrations: phenylephrine (10 µmol/L), insulin (100 nmol/L) and rapamycin (100 
nmol/L). 
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pSILAC and Click-It Chemistry using Invitrogen alkyne agarose resin beads 
ARVCs were cultured in complete M199 medium (M199 medium containing 5.55 
mmol/L glucose, 0.68 mmol/L glutamine, 5 mmol/L creatine, 2 mmol/L-carnitine, and 
5 mmol/L taurine) after isolation; 30 min prior to any treatments, ARVCs were 
transferred into customized M199 media (Dundee Cell Products) containing 0.41 
mmol/L heavy lysine and 0.71 mmol/L heavy arginine, or 0.41 mmol/L medium lysine 
and 0.71 mmol/L medium arginine. Both media contain low levels of methionine 
(25.13 µmol/L, about 25% of that in the standard M199 medium). After 30 min, 
ARVC were treated with various inhibitors in the presence of 2 mmol/L 
azidohomoalanine (AHA). Forty-eight h later, cells were washed twice with cold PBS 
and lysed in pSILAC lysis buffer (8 mol/L urea, 300 mmol/L Tris-HCl pH 8, 4% (w/v) 
CHAPS, 1 mol/L NaCI) containing proteinase inhibitors. 400 µg of lysate from the 
control and treatment animals were mixed together. The mixed protein lysates were 
reacted with alkyne agarose resin beads. The click reactions were conducted 
according to the manufacturer’s instructions (Life Technologies: catalog number C-
10416), after which, the newly-synthesized proteins were covalently conjugated to 
the alkyne-agarose resin beads. They were then digested using 0.1 µg Lys-C for 4 h, 
followed by trypsin digestion (0.1 µg/µl X 1µl 37°C overnight) and subjected to mass 
spectrometry analysis, as reported by the authors (17). Replicate experiments were 
performed, three in the case of insulin and four for PE. This procedure is 
summarised in Figure 1.  
 
Liquid Chromatography - Mass Spectrometry analysis  
Peptide mixtures were de-salted with 100 µl capacity C18 tips (Thermo Scientific) 
with five incremental iterations from 2 to 98% HPLC grade acetonitrile (Fisher 
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Scientific) in 0.1% analytical grade formic acid (Fisher Scientific). Eluates were 
lyophilized to dryness and reconstituted in 20 µl of loading solution (2% acetonitrile, 
0.5% formic acid). A sample of volume 14 µl was then injected onto a C18 µ-
Precolumn (300 µm ID X 10 mm L, 5 µm particle; 100 Å pore size, Acclaim 
PepMap100, Thermo Scientific) at 20 µl/min for 6 min using the loading solution as 
the mobile phase to trap and de-salt its peptide content. The purified peptides were 
then loaded onto a high-capacity nano-capillary reverse phase C18 column (75 µm x 
50 cm, 2 µm particle; 100 Å pore size; Acclaim PepMap 100 column, 
ThermoScientific) retrofitted to a PicoTip nESI emitter (New Objective) and gradient 
separated as reported by the authors (17). Nanospray ionization was conducted at 
2.4 kV and ions were characterized with an FT-Orbitrap Elite (Thermo Scientific) at 
240,000 mass resolution. The top 12, +2 and +3 precursor ions per mass 
spectrometry (MS) scan (minimum intensity 1000) were characterized by high-
energy collisional dissociation (HCD; 15,000 mass resolution, 1.2 Da isolation 
window, 40 keV collision energy) and collision-induced dissociation (CID; ion trap 
MS, 2 Da isolation window, 35 keV) with a dynamic exclusion (5 ppm) of 200 s.  
MS data processing. Peptide spectrum matching and quantifications were performed 
with Proteome Discoverer 1.4 (Thermo Scientific) with SequestHT against the 
UniprotKB SwissProt Rattus norvegicus proteome (downloaded 04/2014; 28861 
entries). For matching and quantitation, precursor tolerance was set at 10 and 3 
ppm, respectively. Fragment matching was set at 0.02 and 0.5 Da for HCD and CID, 
respectively. Target– decoy searching allowed for 1 missed cleavage, a minimum 
length of 6 residues and a maximum of three variable (1 equal) modifications of Met-
AHA (M), deamidation (Asn, Gln), or phosphorylation (Ser, Thr or Tyr). 
Carbamidomethyl (Cys) was set as a fixed modification with Lys (+4 Da), Arg (+6 
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Da), and Lys (+8 Da), Arg (+10 Da) searched to determine medium and heavy 
labeled peptides, respectively. The false discovery rate (FDR) was estimated with 
Percolator at <5% peptide FDR to enable parallel protein grouping and quantitation. 
The mass spectrometric proteomic data have been deposited to the 
ProteomeXchange Consortium (25) via the PRIDE partner repository (26, 27) with 
the dataset identifier PXD004127.  
Protein Hierarchical Clustering Analysis and MetaCore pathway analysis 
Heat-map construction of proteins analysed in at least one replicate of all four 
conditions (i.e. Ins vs. control, PE vs. control, Ins+Rapa vs. Ins, PE+Rapa vs. PE) 
was generated using Cluster 3.0 
(http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm) and Java Treeview 
(http://jtreeview.sourceforge.net). MetaCore (GeneGo, St. Joseph, MI, USA) was 
applied to identify over-represented biological processes and to identify direct protein 
interaction networks of proteins of interest. FDR-corrected P values < 0.05 were 
considered significant.  
 
pSILAC plus click chemistry using Invitrogen alkyne biotin 
ARVC were cultured and treated as described above, and then lysed in cell lysis 
buffer (1% Triton® X100, 50 mmol/L β-glycerophosphate, 1 mmol/L EDTA, 1 mmol/L 
EGTA, 0.5 mmol/L Na3VO4, 1 mmol/L-dithiothreitol, and proteinase inhibitor cocktail; 
Roche, catalog number 11873580001). Protein concentrations were determined by 
Bradford assay. 50-200 µg newly-synthesized proteins were reacted with biotin-
alkyne, according to the procedure described in detail in the manufacturer’s 
instructions (Life Technologies: C-10276). Forty µL of click reaction products were 
subjected to SDS-PAGE, then transferred onto a nitrocellulose microporous 
!!
12!
membrane, which was blocked with 5% (w/v) fat-free powdered milk in PBS-0.02% 
(v/v) Tween. After three washes with PBS-0.02% (v/v) Tween, the membrane was 
incubated with streptavidin, Alexa Fluor® 680 (1:10,000 dilution; 45 min) and, after 
another three washes, the membrane was scanned using the Odyssey® Infrared 
Imaging System. 
 
5’-RACE (rapid amplification of cDNA ends) 
One µg of total RNA from rat heart and a gene-specific primer were used to generate 
the first strand cDNA containing the 5’-UTR and part of the coding region of mRNA, 
then use RNAase H to degrade the mRNA template. Afterwards, the first-strand 
cDNA was ligated with the DNA oligo linker by T4 RNA ligase. The sequence of this 
DNA oligo is 5’-CGTTTGCGAGCAGCGTGGCA-3’, the 5’-end of the oligo is 
phosphorylated, and its 3’-OH is blocked to eliminate self-ligation of the linker. Thus, 
the unknown 5’-UTR can be amplified by primer pairs complementary to the linker 
and the coding sequence region. In order to achieve better amplification efficiency, 
nested PCR (two rounds of PCR with different reverse primer) is required. The PCR 
product was purified using a gel extraction kit and then sent for Sanger sequencing. 
 
Measuring specific newly-synthesized proteins by Click reaction 
Isolated ARVC were cultured and treated with insulin/PE as described above. AHA 
(2 mmol/L) was added into the medium immediately after the treatment; 48 h later, 
cells were lysed, and endogenous ACO2 was immunoprecipitated (IP’d) from 250 µg 
of total lysate protein. IPs were divided into two equal portions; one was analysed by 
western blot to verify the IP efficiency, while the other as used for verification of the 
pSILAC data. IPs were subjected to SDS-PAGE, proteins were transferred onto a 
nitrocellulose membrane and the membrane was blocked with 5% (w/v) fat-free 
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powdered milk in PBS-0.02% (v/v) Tween. After three washes with PBS-0.02% (v/v) 
Tween, the membrane was incubated with 1x reaction buffer (prepared in 
accordance with the manual of Click-iT® Protein Enrichment Kit, Life Technologies: 
C-10416) containing biotin-alkyne overnight. After the click reaction, the reaction 
solution was discarded, and the membrane was washed three times with PBS-0.02% 
(v/v) Tween. Finally, the membrane was incubated with Streptavidin, Alexa Fluor® 
680 (1 in 20,000 dilution) for 45 min; after another three washes, the membrane was 
scanned using the Odyssey® Infrared Imaging System. 
 
Cell culture, cell lysis, western blotting, immunoprecipitation, quantitative real-
time PCR, and measurement of protein synthesis rates.  
HEK293 cells were cultured in complete DMEM (Dulbecco’s modified Eagle’s 
medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 2 mmol/L L-
glutamine. Penicillin G and streptomycin sulphate were also added to the medium to 
final concentrations of 100 units/ml and 100 µg/ml, respectively). Other procedures 
have already been described (28). 
 
5’-RACE primers used in this study are listed in Supplemental Table 1. 
 
Measuring newly synthesized specific proteins by [35S]-methionine labeling 
Isolated ARVC were cultured and treated with insulin or PE as described above, 
[35S]methionine (Perkin Elmer; 10 µCi/mL) was added into the medium; 48 h later, 
cells were lysed, and endogenous HSP60 was IP’d from 250 µg total lysate. IP’s 
were subjected to SDS-PAGE and Coomassie brilliant blue staining and newly-
synthesized HSP60 in the dried gel was visualized by autoradiography. 
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Protein extraction from tissues 
All mouse or rat tissues (20 mg) were frozen and were pulverised in liquid nitrogen 
with a mortar and pestle, then lysed with 400 µL RIPA buffer (50 mmol/L Tris HCl 
7.4, 150 mmol/L NaCl1% Triton X-100 1% sodium deoxycholate, 0.1% (w/v) SDS, 
and proteinase inhibitors (Roche, complete, EDTA-free Protease Inhibitor Cocktail. 
Catalogue number: 11873580001)). Protein concentrations were determined by the 
BCA method. 
 
RNA extraction from tissues 
All mouse or rat tissues (20 mg) were homogenised in liquid nitrogen with a mortar 
and pestle, then lysed with 1ml TRIzol®, the following steps of RNA extraction can 
be found in manufacturer’s instructions (Life Technologies: 15596-018). qPCR 
primers used in this study are listed in Supplemental Table S2.!Rat 18S rRNA 
primers for qPCR were from Primerdesign, Southampton, UK. 
 
Transverse aortic constriction (TAC) 
Animals, surgical interventions, clinical assessment, and echocardiographic 
confirmation of cardiac hypertrophy were described as in (23) (total number of rats = 
24).  
 
Exercise-induced cardiac hypertrophy 
Animals at 3 weeks of age were randomly assigned to either the training or the 
control group (sedentary). The rats in the training group were exercised on a 
treadmill over a period of 10 weeks with 16% incline, a speed of 25 m/min, and 4 
training episodes per week (Monday, Tuesday, Thursday, and Friday). Running 
times were incrementally increased as follows: 30 min/d in the first week, 45 min/d in 
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the second week, 60 min/d in the third, 75 min/d in the fourth week, 90 min/d in the 
fifth week, 105 min/d in the sixth week, and 120 min/d in the last 4 weeks. After 2 
and 6 weeks and at the end of the training protocol, animals were analyzed for 
echocardiographic and in vitro examination. As reported earlier, this training regime 
induces cardiac growth, manifested as an increased heart weight/body weight ratio 
and other parameters associated with CH (29).  
 
Experiment with pregnant mice 
C57Bl6/J mice (females were approximately 4 months of age at the time of 
euthanization; males were 2-6 months of age at time of mating) were mated and 
females were checked for plugs daily (total mice number = 38). Once they had 
plugged, female mice were removed to a separate cage; this was considered day 1 
of pregnancy. Control mice comprised female mice that plugged but were not 
pregnant or equivalently-aged mice that had not been mated. Mice were euthanized 
by cervical dislocation at the indicated times post-insemination and their hearts 
rapidly dissected out. All mice were confirmed pregnant via dissection and visual 
inspection of the uterus. 
 
Determination of cell size 
ARVC were seeded on laminin-coated glass coverslips and treated with vehicle 
control or insulin (100 nmol/L) for 48 h. After treatment, cells were washed twice in 
phosphate buffered saline (PBS, 18912-014, Gibco) and then fixed in 4% 
formaldehyde (F8775, Sigma-Aldrich) for 15 min. Fixed cells were washed again 
thrice with PBS and then labeled with 1X Cellmask stain (C10046, Life 
Technologies) and mounted in Prolong® Gold Antifade Mountant (contains 4',6-
diamidino-2-phenylindole (DAPI), P36935, Life Technologies). Cells were visualized 
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using Leica TCS SP8X/MP microscope equipped with a tuneable white light laser 
using a 40 x oil immersion objective lens (NA = 1.30) numerical aperture objective. 
The cross-sectional area was estimated at the center plane of the cell. Relative cell 
size was then determined using the Leica Application Suite X (LAS X) software 
(version 1.1.0.12420). 
 
Statistical analysis 
Data from independent experimental replicates were analysed using Student’s t-test, 
Significance was set to p = 0.05. 
 
RESULTS 
Proteomics Methodology Optimization 
ARVC do not divide in culture and show low rates of protein synthesis 
(measured as [35S]methionine incorporation), which are only about 5% of the rates in 
HEK293 cells, a cell line which proliferates rapidly in culture (Figure 2A). Our 
preliminary data (not shown) indicated that applying the pSILAC approach alone was 
unable to detect sufficient amounts of labeled peptides with adequate sensitivity due 
to the masking and/or suppression effects of the highly abundant, non-labelled 
background signal from pre-existing proteins. Further investigation showed that 
levels of ribosomal proteins and translation factors are low in normal rat heart 
compared to tissues that maintain higher protein synthesis rates such as pancreas or 
liver (Figure 2B). The AHA-containing newly-synthesized proteins generated by our 
modified approach were captured with approximately 90% efficiency by the alkyne 
agarose resin beads (Figure 2C).  
To improve the efficiency of AHA labeling, we placed ARVC in methionine-
free medium; this increased the efficiency of [35S]methionine incorporation nine-fold 
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(data not shown). However, methionine itself, an essential amino acid, can regulate 
mTORC1 signaling (30), so we needed to use methionine concentrations which 
allowed better AHA incorporation efficiency without affecting the mTORC1 signaling 
pathway. Decreasing the concentration of unlabeled methionine in the M199 medium 
from 50% to 25% of the standard one also doubled the signal (Figure 2D). Increasing 
the labeling time from 24 h to 48 h resulted in approximately a doubling of the signals 
(Figure 2D). Mass spectrometric data (not shown) showed that 48 h labeling-time 
and a methionine concentration of 25.13 µmol/L in M199 medium provide good 
conditions to use for ARVC (and increased the number of proteins identified at 24 h 
from 105 to 167, not shown).  
ARVC are particularly challenging cells in which to study protein synthesis 
due to their very low intrinsic rates of protein synthesis (as documented in this 
report). This is true whether one uses radiolabeled amino acids (which we have 
utilised previously, e.g., (15)) or stable isotope labelling methods (as used here). In 
such primary cells, to ‘scale’ this kind of experiments to the desired objectives, 
[35S]methionine incorporation should be performed prior to experiments using AHA 
labelling. If the rate of protein synthesis in the target cells is similar to cells such as 
HeLa, 6 h pulse labeling is sufficient to identify 300-400 proteins (16). On the other 
hand, if the protein synthesis rate in the cells of interest were only 5% compared to 
HeLa (as it is for ARVCs), then a substantially longer time of labeling would be 
required (to identify a similar number of proteins, it is theoretically necessary to use a 
20-times longer time incubation period). In this case, we labeled for 48 h, the longest 
feasible time (because, as already noted, ARVCs can only be maintained in culture 
for a limited period). To help overcome this limitation, we combined pulsed SILAC 
with AHA labeling to permit us to purify newly-made proteins and remove the un-
labeled proteins which generate peptides that co-elute with, suppress and mask the 
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presence of labeled proteotypic peptides of interest. For each biological replicate, 
0.9-1.2 million ARVCs were used. 
To bypass the need to use offline liquid chromatographic peptide purification 
and separation while preserving proteome coverage, the peptides were on-line de-
salted and concentrated with a high-capacity C18 µ-Precolumn (300 µm X 10 mm, 5 
µm particle; 100 Å pore size) and then loaded onto the 50-cm length reverse phase 
C18 ultra-performance nano-capillary column as reported by the authors (17). Such 
an on-line chromatographic configuration exhibited the satisfactory loading capacity 
and separation efficiency needed to cope with the 400 µg total protein, which was 
injected for each biological replicate run. This approach was, in part, originally 
developed and applied by Thakur et al. (31) for the deep and sensitive proteomic 
analysis of yeast cell lysates in a single 8-h LC-MS analysis run. 
 Over 48 h, PE and insulin increased the overall protein synthesis rates in 
ARVC roughly 1.5 fold and 1.9 fold (Figure 2E), respectively, in line with our previous 
data (32). Moreover, the intensities of all the visible radiolabeled bands were 
increased by insulin and by PE (Figure 2E). [35S]Methionine incorporation measures 
global changes in protein synthesis rates, but cannot easily be used to study 
changes in the synthesis of different protein species (Figure 2E), whereas our new 
method does readily allow us to identify and quantify changes in rates of synthesis of 
specific proteins (Figure 1).  
 
PE and insulin each increase the synthesis of many proteins in ARVC 
Our previous work showed that 48 h PE treatment promotes hypertrophic 
growth of ARVC in vitro. A recent study showed that excessive activation of the 
insulin signaling pathway contributes to the development of pathologic cardiac 
hypertrophy (8). In the present study, we measured the size of ARVC after insulin 
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treatment (100 nM). The data show that 48 h of insulin treatment significantly 
increases the cells’ size (Supplemental Figure S1A,B). Insulin treatment increased 
the levels of expression of the hypertrophy-associated genes for ANF and BNP 
(Supplemental Figure S1C). Our data support the conclusion that high-dose insulin 
treatment causes hypertrophic growth of ARVC that resembles more the pathological 
type. However, insulin does elicit different responses from PE; for example, PE 
activates the MEK-ERK signaling pathway, which has been shown to play an 
important role in overload-induced CH (15, 33, 34). On the other hand, insulin 
activates the PI3K-AKT-mTORC1 signaling pathway (15).  
The LC-MS data (Supplemental Tables S3-S17) show that treatment with PE 
or insulin increases the synthesis of various categories of proteins including 
enzymes of glycolysis, the Krebs cycle and fatty acid β-oxidation as well as proteins 
involved in the cytoskeleton and the contractile machinery. Consistent with the fact 
that both stimuli cause growth of ARVC and are involved in cardiac hypertrophy in 
vivo, there is considerable qualitative overlap between the sets of proteins, which are 
upregulated by the two stimuli. As a means to verify the LC/MS/MS analysis 
efficiency, the signal response to all proteotypic peptides listed in the reported 
proteins /peptide lists gave an analytical confidence > 95%. Close inspection of the 
precursor and product ion spectra of proteotypic peptides exhibited satisfactory 
signal-to-noise ratios with no appearance of low or saturated ion signal responses. 
Our method selectively analyses newly-synthesized proteins and exhibits a wide, 
linear dynamic range capturing proteins ranging from those occurring at higher 
abundance levels (i.e. cytoskeletal proteins) down to proteins at lower abundance 
ARVC proteins such as PKM2 and translation factors, which likely also contribute to 
the overall metabolic remodeling associated with CH. Furthermore, in silico Pathway 
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Map analysis (using MetaCore), necessarily restricted only to those proteins 
identified with an altered synthesis rate (Figure 3A, Supplemental Tables S3 and 
S18), against the entire rat genome confirmed that glycolysis and gluconeogenesis 
[FDR (False Discovery Rate)-corrected P-value = 4.4e-5], mitochondrial long chain 
fatty acid β-oxidation (FDR-corrected P-value = 7.7e-5), muscle contraction/GPCRs 
in the regulation of smooth muscle tone (FDR-corrected P-value = 4.1e-3), and 
muscle contraction/regulation of eNOS activity in cardiomyocytes (FDR-corrected P-
value = 1.3e-2), were significantly over-represented biological processes. We 
recognize that this analysis is limited by the fact that even this enhanced QuaNCAT 
method cannot identify and quantify all the proteins whose synthesis rates is 
changed.  
Insulin and PE promote the synthesis rates of similar sets of proteins. 
However, for some proteins the effect of insulin is stronger than PE, for example, 
insulin increases the synthesis rate of Atp5a1 to 504% and PE increases the 
synthesis rate of Atp5a1 only to 139%, so the effect of Insulin in the synthesis of 
atp5a1 is much stronger than PE, then we list top ten proteins in this category whose 
synthesis was more strongly increased by insulin than by PE (Figure 3B). The data 
are plotted as (change in synthesis caused by insulin- change caused by 
PE)/change caused by PE as a percentage. Those proteins are linked to the 
biological functions energy metabolism (7 proteins), the cytoskeleton (1 protein), or 
mRNA translation (2 proteins). All these functions appear relevant for the healthy 
growth of ARVC, e.g., during compensated hypertrophy. A direct interaction network 
of all proteins whose synthesis was found to be differentially regulated after PE or 
insulin treatment illustrates which of these proteins are functionally interlinked 
(positive or negative regulation, Figure 4).  
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Three important points emerge from the data in Supplemental Table S3 and 
the first two columns of Figure 3A. Firstly, insulin and PE each increase the 
synthesis of almost all the identified proteins. Interestingly, in almost all cases, 
insulin increases the synthesis of individual proteins more than PE in line with its 
greater effect on overall protein synthesis (Figure 2E). Secondly, the effect of insulin 
on synthesis of certain metabolic enzymes is greater than its effect on general 
protein synthesis. Thirdly, the quantitative differences between insulin and PE differ 
across most protein categories, some being increased by insulin much more than 
others, relative to PE, e.g., Dld (dihydrolipoamide dehydrogenase, required for 
mitochondrial energy metabolism), Etfa (electron transfer flavoprotein, α-polypeptide, 
mediates the initial step in mitochondrial oxidation of fatty acids), GAPDH (now 
known to catalyse a limiting step in glycolysis, (2)) and Atp5a1 (a subunit of the 
mitochondrial ATP synthase) (Figure 3B). Indeed, seven of the top ten proteins in 
this group are enzymes involved in energy metabolism, i.e., the Krebs cycle, 
glycolysis or β-oxidation. In particular, GAPDH, which is now known to be the 
regulatory enzyme of glycolysis under aerobic conditions (35), was much more 
strongly increased by insulin than by PE (Figure 3A,B). These changes likely 
promote a more robust and resilient metabolic profile in insulin-induced hypertrophy. 
In contrast, the differences between the effects of PE and insulin on synthesis rates 
are almost non-existent for most heat shock proteins and less pronounced for many 
cytoskeletal components (Supplemental Tables S3-S17). These quantitative 
differences for different proteins indicate the existence of clear differences between 
the effects of the two stimuli studied on the synthesis of specific proteins, rather than 
simply differences in the magnitude of their effects on all proteins across the board. 
Our data suggest that rapidly after hypertrophic stimulation, the synthesis rates of 
many metabolic enzymes are increased, likely to support the increased demand for 
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energy. This could help to explain increased cardiac performance in the 
compensation stage shortly after pressure overload. The quantitative differences 
between the rapid effects of insulin and PE in cultured ARVC presumably reflect 
intrinsic differences between these two stimuli rather than differences due to cardiac 
morphology or overall metabolism. 
Validation of altered synthesis of candidate proteins  
To validate increased rates of synthesis of specific proteins, we first employed 
the ‘traditional’ method of [35S]methionine labeling, followed by IP with a specific 
antibody and autoradiography. This method depends upon having an antibody which 
works well in IP. We tested >10 different antibodies against various candidate 
proteins, and found, for example, that an HSP60 (heat shock 60 kDa protein 1) 
antibody was suitable. Our data show that the accumulation rates of HSP60 are 
indeed increased by insulin and PE in ARVC (Figure 5A). However, the total levels of 
HSP60 were not changed by 48 h of insulin or PE treatment (Figure 5C), likely 
because ARVC already contain appreciable amounts HSP60 so the increased rate 
of synthesis over 48 h does not discernibly affect its total levels. In vivo, CH occurs 
over a longer time period, over which levels of these proteins may indeed change 
significantly. 
AHA labeling provides a non-radioactive alternative to [35S]methionine 
incorporation for assessing changes in the synthesis rates of individual proteins. A 
strategy comprising AHA labeling, IP with a specific antibody and ‘clicking’ to biotin 
followed by visualization using fluorescently-labeled streptavidin can thus be used to 
validate the accumulation rate of candidate proteins (Supplemental Figure S2). 
Using this new method, we found that the accumulation rate of ACO2 (aconitase 2), 
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a mitochondrial protein involved in the Krebs cycle, was increased by insulin or PE 
(Figure 5B). 
If some candidate proteins have low initial levels and/or the accumulation rate 
is very high, one may see a change in total protein levels even after only 48 h. We 
did indeed observe that, after 48 h labeling, the total level of desmin (as assessed by 
western blot) was increased by both insulin and PE. Insulin also modestly but 
consistently upregulated the total protein levels of PKM2 and eEF2 (Figure 5C). In 
heart, the dominant pyruvate kinase isoform is normally PKM1 (36). PKM1 and 
PKM2 are encoded by distinct mRNAs derived from the same transcript by 
alternative splicing, which involves polypyrimidine-binding protein 1 (PTBP1), 
hnRNPA1 and hnRNPA2. The protein levels of PKM1 and PTBP1 in ARVC were not 
changed after insulin treatment (Supplemental Figure S3A). 
The translation elongation factor eEF2 is encoded by a TOP mRNA; such 
mRNAs contain, immediately adjacent to the 5’-terminal cap structure, a terminal 
tract of oligopyrimidines (TOP) which confers control by mTORC1. mTORC1 
promotes the translation of TOP mRNAs. In ARVC, early studies revealed that 
cardiac hypertrophy is accompanied by increased ribosome levels in the 
myocardium (37). We used western blot analysis to examine another protein which 
was detected in the proteomic analysis, and is encoded by a TOP mRNA (38), i.e., 
eEF1G, part of the complex that regulates elongation factor eEF1A (39) 
(Supplemental Table S3). We found that the level of eEF1G protein was also 
upregulated by insulin in ARVC (Figure 5C). Upregulation of elongation factors by 
mTORC1 likely contributes to longer-term mass accumulation during cardiac 
hypertrophy by increasing the cellular capacity for protein synthesis. Levels of the 
small ribosomal subunit protein S6, encoded by another TOP mRNA, were also 
slightly increased by insulin (Figure 5C).  
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Increased synthesis of specific proteins reflects increased translation of their mRNAs, 
not increased mRNA levels 
Increased synthesis of a given protein could reflect enhanced translation of 
similar levels of mRNA or, especially after periods as long as 48 h (the labeling time 
used here), higher mRNA levels due to enhanced gene transcription. We therefore 
also determined, by RT-qPCR, the total mRNA levels of selected candidate proteins: 
ACO2, HSP60, myoglobin, desmin and an acyl-coenzyme A dehydrogenase (Acadl). 
Their mRNA levels were either unchanged or rose much less than the rates of 
synthesis of the corresponding proteins (Figure 5D,E). For example, although 
desmin mRNA levels increased in response to insulin or PE, this effect was much 
smaller (1.2- or 1.5-fold) than the 8 or >3 fold changes in the synthesis of desmin 
itself (Figure 5E). Thus, insulin and PE regulate the synthesis of these proteins 
primarily by increasing the translation of their mRNAs. 
 
PE and insulin activates synthesis of specific proteins in ARVC via mTORC1  
As noted, both PE and insulin activate mTORC1 signaling in ARVC (15, 33, 
34), and mTORC1 also plays a key role in cardiac hypertrophy (11, 12, 40, 41). To 
test the role of mTORC1 signaling in regulating the synthesis of specific proteins in 
ARVC, we repeated the AHA-pSILAC labeling experiments using ARVC that were 
treated with PE or insulin in the presence of the mTORC1 inhibitor rapamycin 
(RAPA). Hierarchical clustering analysis, presented in heat-map format (Figure 3A), 
revealed distinct ARVC proteome expression profiles for insulin over control and PE 
over control relative to the insulin + rapamycin over insulin and PE + rapamycin over 
PE datasets. Interestingly, rapamycin decreased the synthesis rate of almost every 
protein observed (Figure 3A, Supplemental Tables S18-S30). The direct protein 
interaction network analysis performed for all differentially expressed proteins after 
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insulin/PE treatment vs. control and insulin/PE +Rapa treatment vs. control, shows 
that a number of those proteins are functionally interlinked (positive or negative 
regulation, Figure 4A and B). 
For insulin, rapamycin generally decreased rates of synthesis by 45-60%. The 
greatest inhibition (by almost 75%) was seen for eEF2, which is encoded by a TOP 
mRNA. Rapamycin also strongly inhibited the synthesis of GAPDH, as reported to be 
controlled by mTORC1 in HeLa cells by the authors (16), and desmin, which showed 
the greatest increase in response to insulin. Rapamycin also inhibited the PE-
induced increases in the synthesis of every protein, but to a lesser extent (typically 
by 35-50%) than insulin, in line with the fact that PE also stimulates synthesis of 
these proteins less than insulin. Again, the strongest effect was observed for eEF2, a 
protein encoded by a TOP mRNA. These data indicate that increased synthesis of all 
these proteins is promoted by mTORC1 signaling, in line with our earlier observation 
that mTORC1 plays a substantial role in the control of protein synthesis by PE or 
insulin in ARVC (32). 
 
Determination of the 5’-UTR of candidate mRNAs 
Given mTORC1’s major role in regulating synthesis of many proteins at the 
translational level in ARVC and that mTORC1 promotes translation of TOP mRNAs 
(42), it was of interest to determine the sequence of the 5’-UTRs of selected 
candidates. We therefore employed a method which is based on a previously 
published approach (43). Using this method (Supplemental Figure S4), we 
determined the sequence of the 5’-UTRs of the mRNAs encoding desmin, ALDOA 
(aldolase A) and JUP (junction plakoglobin) in ARVC (Supplemental Figure S5, 
Figure 5F). These are not TOP mRNAs and do not possess the pyrimidine-rich 
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translational element previously reported to play a role in mTORC1-mediated 
translational control (44). Their 5’-UTRs are actually short and unstructured, so they 
do not resemble the types of structured mRNAs thought to be controlled by the 
mTORC1-regulated eIF4F complex. Interestingly, we have previously shown that PE 
regulates protein synthesis in ARVC by mechanisms that depend on mTORC1 but in 
an eIF4F-independent manner (45).  
 
PKM2, and eEF1G are upregulated in TAC induced hypertrophy, but not in 
physiological CH models 
TAC (transverse aortic constriction) is a classic model of pathological cardiac 
hypertrophy caused by pressure overload, and induces increased heart size (relative 
to body weight and other hallmarks of CH (46). TAC induces activation of mTORC1 
(11, 47), which is important in mass accumulation following TAC. Our data show that, 
two weeks after TAC, three out of six rats still exhibited very high levels of mTORC1 
signaling (rpS6 p240/244 phosphorylation) (Figure 6A), so it was of interest to study 
whether candidate proteins identified by pSILAC were also upregulated in the TAC-
rat model. 
Expression of PKM2 was elevated following TAC at the 6 week time point 
(Figure 6 A-C), indicating that PKM2 may play important roles in this setting. 
Expression of eEF1G is upregulated in the TAC model at both 2- and 6-week time-
points. Increased expression of translation factors in the TAC model likely helps 
support the faster protein synthesis that leads to mass accumulation during cardiac 
hypertrophy. The mRNA levels for eEF1G in TAC samples were not changed (Figure 
6D,E), indicating its upregulation is at a translational level. The mRNA for desmin 
was slightly upregulated (20%); however, desmin protein levels in TAC samples 
were unaltered, which differs from what was observed in ARVC in culture. Using two-
!!
27!
dimensional electrophoresis (2-DE) and mass spectrometry, it was found that, at 48 
weeks, when left ventricular hypertrophy is established, desmin protein levels are 
upregulated (48). In order to assess whether PKM2 and eEF1G were also 
upregulated in physiological cardiac hypertrophy model, we used Western blot 
analysis samples from in exercise-induced CH heart (rat), and hearts from pregnant 
mice, because two independent studies didn’t see CH in pregnant rats, even though 
cardiac function was clearly enhanced (49, 50). Our data show that PKM2 and 
eEF1G were not up-regulated in those two models (Supplemental Figure S6), 
indicating PKM2 and eEF1G were specifically up-regulated in pathological CH. 
Interestingly, a recent study reported that PKM2 is also upregulated in the heart of 
mice treated with sunitinib, an anti-cancer drug whose use is associated with heart 
failure (51). We found that protein levels of PKM1 and PTBP1 in TAC samples were 
not changed (Supplemental Figure S3B,C). 
 
Chronic activation of mTORC1 in MEFs upregulates the expression of candidate 
proteins 
For candidate proteins whose synthesis is regulated by mTORC1 signaling in 
ARVC, chronic activation of mTORC1 is expected to upregulate their total levels. 
Since loss of TSC2, a negative regulator of mTORC1, leads to constitutive activation 
of mTORC1 (52), we determined the total protein and mRNA levels for several 
candidates in wild-type and TSC2-/- MEFs (Figure 7). This will tell us whether the 
candidates identified in ARVC are heart cell-specific or universal. 
The results clearly show that the protein levels of ALDOA, ACO2, JUP and 
MDH2 are elevated in TSC2-/- MEFs compared to wild-type MEFs, especially for 
JUP, which was not detectable in wild type MEFs, but expressed at substantial levels 
in TSC2-/- MEFs (Figure 7A). The Jup mRNA level was also increased by almost 4-
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fold in TSC2-/- MEFs. The mRNA for ALDOA was not affected by activation of 
mTORC1, but its protein levels in TSC2-/- MEFs are about 2.3-fold higher than in 
wild-type MEFs (Figure 7B,C). These results indicate that mTORC1 regulates the 
expression of ALDOA at the translational level. In MEFs, expression of MDH2 and 
ACO2 were also upregulated by mTORC1, but are probably regulated at the 
transcriptional level in MEFs, which differs from the situation observed in ARVC 
(Figure 5E). 
 
DISCUSSION 
Here, we report the refinement and novel application of a recently-developed 
QuaNCAT proteomics approach (19, 53) to analyse the synthesis rates of specific 
proteins in response to stimulation of ARVC with pro-hypertrophic agents. This 
approach provides an unbiased and effective means to quantify changes in the 
synthesis of many proteins in parallel, even in cells with low ongoing rates of protein 
synthesis. We have also developed a new and effective method for validating 
changes in the synthesis of specific proteins identified using this approach. Both of 
these approaches will be valuable for studying changes in the synthesis of specific 
proteins in a wide range of cell-types and conditions.  
Our QuaNCAT proteomics data reveal that, in response to hypertrophic 
stimulation, the synthesis rates of many proteins increase markedly even over the 
first 48 h. Insulin and PE each increase the synthesis of a wide range of proteins. 
According to the prior literature, the total levels of some of these proteins are also 
upregulated at later stages of pathological CH, e.g., the sarco/endoplasmic reticulum 
Ca2+-ATPase, GAPDH, myoglobin, mitochondrial elongation factor EF-Tu (Tufm), 2-
oxoglutarate dehydrogenase and phosphoglycerate kinase, JUP (Junction 
Plakoglobin), VCL (Vinculin), HSP90aa1, HSP90ab1, Ddx5, eEF1A1, eEF2 (54), 
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filamin-C (34, 54) and ENO1 (20, 54). The accordance between the current study 
and previous ones demonstrates the validity of our newly-developed method. Our 
data also show the elevated synthesis of those proteins in CH is mediated primarily 
at the level of the increased translation of their mRNAs driven by mTORC1 signaling. 
Thus, activation of the synthesis of specific proteins is a very rapid translational 
response to hypertrophic simulation of ARVC, which precedes the long-established 
but slower increase in their translational capacity (ribosomal content) (2). 
Our data also show that PE and insulin promote the synthesis of generally 
similar sets of proteins. However, on average, the increase in their rates of synthesis 
was 102% greater for insulin than PE. For certain specific proteins, the relative rate 
of stimulation between the insulin and PE was found to be even larger (Figure 3A); 
namely, among the top ten proteins in this category, seven were metabolic enzymes, 
and only one was a structural cytoskeletal protein. The differential increase in the 
rate of synthesis of these two groups of proteins is likely to give rise to different 
metabolic outcomes in the two types of settings, since insulin more strongly 
enhances the expression of proteins involved in supplying metabolic energy, which is 
required for enhanced cardiac function. 
As stated, GAPDH is known to be a rate-limiting enzyme for aerobic glycolysis 
(35). Another essential participant to aerobic glycolysis is pyruvate kinase, which 
catalyses the transformation of phosphoenolpyruvate into pyruvate and exists as four 
isoforms, PKL, PKR, PKM1 and PKM2. In adult animals, the dominant form of PK in 
heart is PKM1 (36). Given the role of PKM2 in regulating the channeling of carbon 
atoms into biosynthesis or oxidation (55), the ability of PE and especially insulin to 
increase the synthesis of GAPDH and PKM2 is of particular interest. Interestingly, 
we found that the synthesis of PKM2 is upregulated by PE/insulin via mTORC1 
signaling in ARVC. The levels of PKM2 protein are also upregulated in hearts from 
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animals subjected to TAC. The biological significance of PKM2 is underscored by the 
observation that it plays important roles in tumorigenesis (56). In various types of 
tumours, pyruvate kinase expression shifts to the PKM2 isoform (57). Cancer cells 
make use of anaerobic glycolysis (58) to utilise glucose efficiently to generate 
biomass (the ‘Warburg effect’), i.e., the synthesis of macromolecules required for cell 
growth and division. PKM2 plays a key role in regulating the direction of carbon 
atoms towards biosynthesis or oxidation (55). In TAC rats, upregulating PKM2 likely 
also serves to provide precursors for macromolecular synthesis to support 
cardiomyocyte growth.  
These changes suggest that the alterations in intermediary metabolism 
induced by hypertrophic stimuli are similar to those seen in cancer cells, where 
enhanced metabolic capacity is also a key feature. Additionally, PKM2 is the isoform 
initially expressed in embryonic tissues, so the increased expression of PKM2 during 
TAC may reflect the recapitulation of a fetal gene program. We used five pairs of 
qPCR primers to try to measure Pkm1 and Pkm2 mRNA levels in ARVC or rat 
hearts, but unfortunately, none worked in qPCR, so we were unable to assess the 
mRNA levels for these two isoforms. Since one of the major proteins involved in the 
alternative splicing of Pkm1/2 mRNA and of the PKM1 protein itself are not altered 
(Supplemental Figure S3), it is unlikely that upregulation of PKM2 under pressure 
overload is (solely) mediated by alternative splicing. On the other hand, our data 
indicate that increased translation of PKM2 mRNA is mediated by mTORC1 
signaling, but our data do not allow us to exclude other mechanisms. We cannot 
exclude that other factors may be involved. Rees et al. (51) reported that, in a 
sunitinib induced heart failure mouse model, the PKM2 protein level was up-
regulated by 2 fold, but PKM1 remained unchanged, which is very similar to what we 
observed in the TAC rat model. They also found shift of about 25% from the PKM1 
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mRNA to the PKM2 mRNA. This shift was significant but quite subtle compared to 
the change in protein level (2 fold). Given that sunitinib also increased insulin 
sensitivity in mice, it is highly likely that insulin signaling pathway and increased 
translation also contributed to the up-regulation of PKM2 in their model in addition to 
alternative splicing. Significantly, our data also suggest that inhibiting PKM2 might be 
a new therapeutic approach for pathological cardiac hypertrophy therefore serving as 
a potential biomarker of response to pharmacologic intervention. However, although 
inhibitors of PKM2 such as Shikonin and its analogues have recently been described 
and shown to inhibit cancer cell glycolysis (59), it is not clear that these compounds 
are suitable as therapeutic agents for targeting PKM2, since they also interact with 
PKM1 and other proteins (60).  
We also observed increased expression of one elongation factor (eEF1G), a 
component of the guanine nucleotide that controls the activity of eEF1A, an effect 
that likely contributes to increasing protein synthesis capacity during pathological 
CH.  
The healthy heart normally prefers fatty acids as its energy source (fatty acid 
oxidation provides about 70% of the ATP in healthy heart (61). The heart can also 
use certain other substrates as energy sources, including glucose, lactate, ketones 
and amino acids (62, 63). Such flexibility can help maintain normal function under 
different workloads and circumstances. Metabolic remodeling in heart is a hallmark 
of CH. Under hypertrophic conditions, total ATP production decreases, and the 
proportion of ATP generated by fatty acid oxidation is reduced, while ATP generation 
by glycolysis and lactate oxidation increases. Interventions which block the substrate 
shift from fatty acids to glucose can attenuate TAC-induced cardiac hypertrophy (61). 
Our findings indicate that, following short-term hypertrophic stimulation, the 
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expression of enzymes involved in glycolysis and the Krebs cycle increases, likely as 
an adaptation to the increased demand in ATP. While it is commonly accepted that, 
in failing heart, genes involved in fatty acid β-oxidation are downregulated (64), our 
data showed that synthesis rate of β-oxidation enzymes is also upregulated soon 
after hypertrophic stimulation. Our results suggest that myocytes initially attempt to 
maintain a high level of β-oxidation after hypertrophic stimulation by upregulating 
those enzymes. However, in the decompensation stage of CH, impaired 
mitochondrial biogenesis and mitochondrial defects occur (65), rendering the 
upregulation of those enzymes unfeasible. Interestingly, analogous traits have been 
observed with LC-MS-based quantitative metabolomics studies using a mouse 
model of dilated cardiomyopathy (66) and rat TAC hearts (67).  
Numerous sarcomeric components/cytoskeletal proteins were identified as 
showing increased synthesis in our pSILAC experiments, several of which play 
important roles in cardiac function and/or in cardiomyopathies (e.g., desmin, vinculin, 
NRAP [nebulin-related anchoring protein] and Lmod). Mutations or altered 
expression of those proteins are associated with various cardiac disorders (68-76). 
Our data show that expression of these proteins is regulated by mTORC1 signaling 
in ARVC. 
Indeed, upregulation of the synthesis of all the proteins we identified was 
inhibited by rapamycin indicating it requires signaling through mTORC1 (Figure 8). 
We determined the levels of the mRNAs for several proteins of interest by RT-qPCR. 
mRNA levels were either unchanged or minor indicating that enhanced synthesis of 
these proteins involves increased translation of their mRNAs, rather than increased 
mRNA levels, consistent with the well-established role of mTORC1 in controlling 
mRNA translation. Thus, a key feature of the early response of ARVC to 
hypertrophic stimuli is that translational control underpins the increased synthesis of 
!!
33!
proteins in response to hypertrophic stimuli in ARVC (Figure 8). We have previously 
shown that insulin and PE each activate multiple components of the translational 
machinery in ARVC (15, 33, 34, 77).  
The greatest effect of rapamycin on the synthesis of a specific proteins was 
observed for eEF2, which is encoded by a TOP mRNA. However, the vast majority 
of the proteins whose synthesis was sensitive to rapamycin are not known to be 
encoded by TOP mRNAs. Our novel rapid amplification of cDNA ends (RACE) 
technique confirmed that the desmin, AldoA and Jup mRNAs do not contain a TOP. 
Thus, the synthesis of these proteins is increased via an mTORC1-dependent 
mechanism distinct from the established TOP regulatory system. Interestingly, some 
candidate proteins (ALDOA, MDH2, JUP, ACO2) identified in our pSILAC data are 
not only regulated by mTORC1 signaling in ARVC but also in MEFs. Surprisingly, 
eEF1G and PKM2 protein levels remained unchanged in TSC2-/- cells vs. controls 
(data not shown). 
The study results underscore the notion that our optimized QuaNCAT 
proteomics approach can more effectively quantify proteins with very low synthesis 
rates commonly occurring in cardiomyocytes. However, a significant number of many 
proteins were profiled with a high abundance of “light” proteotypic peptides relative to 
their “medium” or “heavy” counterparts. Although this difference in ion intensities 
may have reduced the linear dynamic range of relative quantitation, this trend had 
negligible effects to the study method’s ability to profile AHA-pSILAC labeled 
peptides that corresponded to proteins with low synthesis rates. Such a performance 
characteristic was extensively verified as part of the method optimization 
experiments. Our proof-of-concept study was intended to assess changes in the 
synthesis rates of specific proteins rather than observing the wider spectrum of 
proteins typically detected under steady-state conditions using non-targeted isobaric 
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labeling approaches or label-free approaches (20-22). Our method selectively 
analysed newly-synthesized proteins and exhibited a wide linear dynamic range 
capturing proteins occurring at the higher native abundance levels (i.e. cytoskeletal 
and contractile proteins) that mapped to the canonical pathway analysis performed 
as well as proteins that occur at the lower native abundance levels (i.e. the 
translation factors eEF1G and eEF2, PKM2) that constitute novel observations of 
this study and provide additional measurable hallmark features in ARVC. Also, the 
performance characteristics of our optimized QuaNCAT method in terms of analytical 
precision, selectivity, accuracy and sensitivity supersedes that of older radiolabeling 
approaches (e.g., with [35S]methionine) for studying the synthesis of specific 
proteins. There are undoubtedly newly synthesized proteins in ARVC that are not 
captured with the method used here due to intrinsic limitations in the enrichment, 
purification and/or subsequent LC-MS detection of peptides. Therefore, the synthesis 
of other proteins of potential interest likely shows differential responses to PE or 
insulin. This does not detract from the basic study goal in that measurable and novel 
differences were indeed observed between the reported stimuli in ARVC. Previous 
studies using label-free and iTRAQ LC-MS proteomics to study the differential 
expression of proteins in hypertrophic or diseased heart (20-22) only examined 
steady-state levels of expression, not alterations in their synthesis rates. Another 
proteomics study using two-dimensional electrophoresis (2-DE) and MALDI mass 
spectrometry, found that, at 48 weeks, when left ventricular hypertrophy was well 
established, 56 proteins were differentially expressed in hearts of spontaneously-
hypertensive rats compared to controls (48). The same group reported only nine 
proteins were differentially expressed at earlier stages of left ventricular hypertrophy 
(22). By contrast, the detection of proteins exhibiting a varying degree of synthesis 
rates and native abundance levels made possible with the QuaNCAT study method 
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were not observed by these proteomics approaches even at steady-state 
concentration levels. Additionally, the degree of proteome coverage for the de novo 
synthesized proteins observed in this study mapped to a wide spectrum of biological 
pathways and networks thus providing a novel synergistic understanding of cardiac 
hypertrophy. 
 
CONCLUSIONS AND FUTURE PERSPECTIVES  
Overall, our data show that, rapidly after PE or insulin stimulation of ARVC, 
there are substantial changes in the synthesis rates of proteins involved in various 
processes including glycolysis, Krebs cycle, β-oxidation, translation, protein folding 
and sarcomeric function. Their regulation requires mTORC1 signaling which 
promotes translation of their mRNAs. Our data thus reveal that ARVCs respond 
rapidly to hypertrophic stimuli by upregulating the synthesis of proteins involved in 
metabolism and cytoskeletal/contractile function, although the responses to PE and 
insulin differ quantitatively for several proteins. The latter aspect may well to a 
considerable extent lead to the differing eventual outcomes to stimulation of heart 
muscle cells by PE or insulin. As a future perspective, the PE and insulin conditions, 
with or without rapamycin, at the reported concentrations levels provide useful new 
insight in the design of functional ARVC in vivo assays to further substantiate these 
study conclusions. Finally, we show that two of these proteins, PKM2 and eEF1G, 
are specifically upregulated in rats subjected to TAC (Figure 7 and Supplemental 
Figure S6). Thus, our proof-of-principle study has identified PKM2 as a candidate 
biomarker of pathological hypertrophy that warrants additional functional validation 
with commercially available small molecule inhibitors in various in vivo models. 
 
  
!!
36!
ACKNOWLEDGEMENTS 
With a grateful to Dr Leonard Foster (University of British Columbia) for excellent 
assistance with mass spectrometry, Dr Andrea Schrepper (Jena) for help in 
preparing the manuscript and to Meiling Lin for art work. We are indebted to Roger 
Allsopp and Derek Coates, for contributing to establishing the FT−MS proteomics 
platform at the University of Southampton. We thank the PRIDE team for proteomics 
data processing, repository assistance, and use of the IRIDIS High Performance 
Computing Facility and associated support services at the University of 
Southampton, especially Elena Vataga.  
 
SOURCES OF FUNDING 
We acknowledge generous funding from the British Heart Foundation and the 
Wellcome Trust. Funding for the proteomics work was provided by the the Wessex 
Cancer Trust and Medical Research, UK, Hope for Guernsey, the University of 
Southampton “Annual Adventures in Research”, the Deanship of Scientific 
Research, Prolific Research Group Program (PRG-1436-15), Vice-Rectorate for 
Graduate Studies and Scientific Research and the Visiting Professor Program of 
King Saud University, Riyadh, Saudi Arabia. 
 
DISCLOSURES 
None. 
  
!!
37!
References 
1. Kavazis, A. N. (2015) Pathological vs. physiological cardiac hypertrophy. J 
Physiol 593, 3767 
2. Morgan, H. E., Gordon, E. E., Kira, Y., Chua, H. L., Russo, L. A., Peterson, C. 
J., McDermott, P. J., and Watson, P. A. (1987) Biochemical mechanisms of cardiac 
hypertrophy. Annu Rev Physiol 49, 533-543 
3. Eghbali, M., Wang, Y., Toro, L., and Stefani, E. (2006) Heart hypertrophy 
during pregnancy: a better functioning heart? Trends Cardiovasc Med 16, 285-291 
4. Kim, J. H., and Baggish, A. L. (2016) Differentiating Exercise-Induced Cardiac 
Adaptations From Cardiac Pathology: The "Grey Zone" of Clinical Uncertainty. Can J 
Cardiol 32, 429-437 
5. Depre, C., Shipley, G. L., Chen, W., Han, Q., Doenst, T., Moore, M. L., 
Stepkowski, S., Davies, P. J., and Taegtmeyer, H. (1998) Unloaded heart in vivo 
replicates fetal gene expression of cardiac hypertrophy. Nat Med 4, 1269-1275 
6. Bernardo, B. C., Weeks, K. L., Pretorius, L., and McMullen, J. R. (2010) 
Molecular distinction between physiological and pathological cardiac hypertrophy: 
experimental findings and therapeutic strategies. Pharmacol Ther 128, 191-227 
7. McMullen, J. R., Shioi, T., Huang, W. Y., Zhang, L., Tarnavski, O., Bisping, E., 
Schinke, M., Kong, S., Sherwood, M. C., Brown, J., Riggi, L., Kang, P. M., and 
Izumo, S. (2004) The insulin-like growth factor 1 receptor induces physiological heart 
growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 279, 
4782-4793 
8. Shimizu, I., Minamino, T., Toko, H., Okada, S., Ikeda, H., Yasuda, N., Tateno, 
K., Moriya, J., Yokoyama, M., Nojima, A., Koh, G. Y., Akazawa, H., Shiojima, I., 
Kahn, C. R., Abel, E. D., and Komuro, I. (2010) Excessive cardiac insulin signaling 
exacerbates systolic dysfunction induced by pressure overload in rodents. J Clin 
Invest 120, 1506-1514 
9. Hannan, R. D., Jenkins, A., Jenkins, A. K., and Brandenburger, Y. (2003) 
Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 30, 517-
527 
10. McMullen, J. R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M. C., Kang, 
P. M., and Izumo, S. (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical 
role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc 
Natl Acad Sci U S A 100, 12355-12360 
11. Shioi, T., McMullen, J. R., Tarnavski, O., Converso, K., Sherwood, M. C., 
Manning, W. J., and Izumo, S. (2003) Rapamycin attenuates load-induced cardiac 
hypertrophy in mice. Circulation 107, 1664-1670 
!!
38!
12. McMullen, J. R., Sherwood, M. C., Tarnavski, O., Zhang, L., Dorfman, A. L., 
Shioi, T., and Izumo, S. (2004) Inhibition of mTOR signaling with rapamycin 
regresses established cardiac hypertrophy induced by pressure overload. Circulation 
109, 3050-3055 
13. Huang, J., and Manning, B. D. (2008) The TSC1-TSC2 complex: a molecular 
switchboard controlling cell growth. Biochem J 412, 179-190 
14. Wang, Y., Huang, B. P., Luciani, D. S., Wang, X., Johnson, J. D., and Proud, 
C. G. (2008) Rheb activates protein synthesis and growth in adult rat ventricular 
cardiomyocytes. J Mol Cell Cardiol 45, 812-820 
15. Wang, L., Wang, X., and Proud, C. G. (2000) Activation of mRNA translation 
in rat cardiac myocytes by insulin involves multiple rapamycin-sensitive steps. Am J 
Physiol Heart Circ Physiol 278, H1056-1068 
16. Huo, Y., Iadevaia, V., Yao, Z., Kelly, I., Cosulich, S., Guichard, S., Foster, L. 
J., and Proud, C. G. (2012) Stable isotope-labelling analysis of the impact of 
inhibition of the mammalian target of rapamycin on protein synthesis. Biochem J 
444, 141-151 
17. Genheden, M., Kenney, J. W., Johnston, H. E., Manousopoulou, A., Garbis, 
S. D., and Proud, C. G. (2015) BDNF stimulation of protein synthesis in cortical 
neurons requires the MAP kinase-interacting kinase MNK1. J Neurosci 35, 972-984 
18. Eichelbaum, K., Winter, M., Berriel Diaz, M., Herzig, S., and Krijgsveld, J. 
(2012) Selective of newly synthesized proteins for quantitative secretome analysis. 
Nat Biotechnol 30, 984-990 
19. Howden, A. J., Geoghegan, V., Katsch, K., Efstathiou, G., Bhushan, B., 
Boutureira, O., Thomas, B., Trudgian, D. C., Kessler, B. M., Dieterich, D. C., Davis, 
B. G., and Acuto, O. (2013) QuaNCAT: quantitating proteome dynamics in primary 
cells. Nat Methods 10, 343-346 
20. Dai, D. F., Hsieh, E. J., Chen, T., Menendez, L. G., Basisty, N. B., Tsai, L., 
Beyer, R. P., Crispin, D. A., Shulman, N. J., Szeto, H. H., Tian, R., MacCoss, M. J., 
and Rabinovitch, P. S. (2013) Global proteomics and pathway analysis of pressure-
overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. 
Circ Heart Fail 6, 1067-1076 
21. Kocher, T., Pichler, P., Schutzbier, M., Stingl, C., Kaul, A., Teucher, N., 
Hasenfuss, G., Penninger, J. M., and Mechtler, K. (2009) High precision quantitative 
proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method 
combining the benefits of all. J Proteome Res 8, 4743-4752 
22. Gallego-Delgado, J., Lazaro, A., Osende, J. I., Esteban, V., Barderas, M. G., 
Gomez-Guerrero, C., Vega, R., Vivanco, F., and Egido, J. (2006) Proteomic analysis 
!!
39!
of early left ventricular hypertrophy secondary to hypertension: modulation by 
antihypertensive therapies. J Am Soc Nephrol 17, S159-164 
23. Schwarzer, M., Schrepper, A., Amorim, P. A., Osterholt, M., and Doenst, T. 
(2013) Pressure overload differentially affects respiratory capacity in interfibrillar and 
subsarcolemmal mitochondria. Am J Physiol Heart Circ Physiol 304, H529-537 
24. Wang, X., Levi, A. J., and Halestrap, A. P. (1994) Kinetics of the sarcolemmal 
lactate carrier in single heart cells using BCECF to measure pHi. Am J Physiol 267, 
H1759-1769 
25. Vizcaino, J. A., Deutsch, E. W., Wang, R., Csordas, A., Reisinger, F., Rios, 
D., Dianes, J. A., Sun, Z., Farrah, T., Bandeira, N., Binz, P. A., Xenarios, I., 
Eisenacher, M., Mayer, G., Gatto, L., Campos, A., Chalkley, R. J., Kraus, H. J., 
Albar, J. P., Martinez-Bartolome, S., Apweiler, R., Omenn, G. S., Martens, L., Jones, 
A. R., and Hermjakob, H. (2014) ProteomeXchange provides globally coordinated 
proteomics data submission and dissemination. Nat Biotechnol 32, 223-226 
26. Vizcaino, J. A., Cote, R. G., Csordas, A., Dianes, J. A., Fabregat, A., Foster, 
J. M., Griss, J., Alpi, E., Birim, M., Contell, J., O'Kelly, G., Schoenegger, A., 
Ovelleiro, D., Perez-Riverol, Y., Reisinger, F., Rios, D., Wang, R., and Hermjakob, H. 
(2013) The PRoteomics IDEntifications (PRIDE) database and associated tools: 
status in 2013. Nucleic Acids Res 41, D1063-1069 
27. Wang, R., Fabregat, A., Rios, D., Ovelleiro, D., Foster, J. M., Cote, R. G., 
Griss, J., Csordas, A., Perez-Riverol, Y., Reisinger, F., Hermjakob, H., Martens, L., 
and Vizcaino, J. A. (2012) PRIDE Inspector: a tool to visualize and validate MS 
proteomics data. Nat Biotechnol 30, 135-137 
28. Liu, R., Iadevaia, V., Averous, J., Taylor, P. M., Zhang, Z., and Proud, C. G. 
(2014) Impairing the production of ribosomal RNA activates mammalian target of 
rapamycin complex 1 signalling and downstream translation factors. Nucleic Acids 
Res 42, 5083-5096 
29. Schrepper, A., Schwarzer, M., Schope, M., Amorim, P. A., and Doenst, T. 
(2012) Biphasic response of skeletal muscle mitochondria to chronic cardiac 
pressure overload - role of respiratory chain complex activity. J Mol Cell Cardiol 52, 
125-135 
30. Hara, K., Yonezawa, K., Weng, Q. P., Kozlowski, M. T., Belham, C., and 
Avruch, J. (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-
4E BP1 through a common effector mechanism. J Biol Chem 273, 14484-14494 
31. Thakur, S. S., Geiger, T., Chatterjee, B., Bandilla, P., Frohlich, F., Cox, J., and 
Mann, M. (2011) Deep and highly sensitive proteome coverage by LC-MS/MS 
without prefractionation. Mol Cell Proteomics 10, M110 003699 
!!
40!
32. Rolfe, M., McLeod, L. E., Pratt, P. F., and Proud, C. G. (2005) Activation of 
protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine 
requires the activation of ERK and involves phosphorylation of tuberous sclerosis 
complex 2 (TSC2). Biochem J 388, 973-984 
33. Wang, L., and Proud, C. G. (2002) Ras/Erk signaling is essential for activation 
of protein synthesis by Gq protein-coupled receptor agonists in adult 
cardiomyocytes. Circ Res 91, 821-829 
34. Wang, L., Gout, I., and Proud, C. G. (2001) Cross-talk between the ERK and 
p70 S6 kinase (S6K) signaling pathways. MEK-dependent activation of S6K2 in 
cardiomyocytes. J Biol Chem 276, 32670-32677 
35. Shestov, A. A., Liu, X., Ser, Z., Cluntun, A. A., Hung, Y. P., Huang, L., Kim, 
D., Le, A., Yellen, G., Albeck, J. G., and Locasale, J. W. (2014) Quantitative 
determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a 
limiting step. Elife 3 
36. Imamura, K., and Tanaka, T. (1982) Pyruvate kinase isozymes from rat. 
Methods Enzymol 90 Pt E, 150-165 
37. Morgan, H. E., Siehl, D., Chua, B. H., and Lautensack-Belser, N. (1985) 
Faster protein and ribosome synthesis in hypertrophying heart. Basic Res Cardiol 80 
Suppl 2, 115-118 
38. Iadevaia, V., Caldarola, S., Tino, E., Amaldi, F., and Loreni, F. (2008) All 
translation elongation factors and the e, f, and h subunits of translation initiation 
factor 3 are encoded by 5'-terminal oligopyrimidine (TOP) mRNAs. RNA 14, 1730-
1736 
39. Le Sourd, F., Boulben, S., Le Bouffant, R., Cormier, P., Morales, J., Belle, R., 
and Mulner-Lorillon, O. (2006) eEF1B: At the dawn of the 21st century. Biochim 
Biophys Acta 1759, 13-31 
40. Lee, C. H., Inoki, K., and Guan, K. L. (2007) mTOR pathway as a target in 
tissue hypertrophy. Annu Rev Pharmacol Toxicol 47, 443-467 
41. Gao, X. M., Wong, G., Wang, B., Kiriazis, H., Moore, X. L., Su, Y. D., Dart, A., 
and Du, X. J. (2006) Inhibition of mTOR reduces chronic pressure-overload cardiac 
hypertrophy and fibrosis. J Hypertens 24, 1663-1670 
42. Meyuhas, O., and Kahan, T. (2015) The race to decipher the top secrets of 
TOP mRNAs. Biochim Biophys Acta 1849, 801-811 
43. Edwards, J. B., Delort, J., and Mallet, J. (1991) Oligodeoxyribonucleotide 
ligation to single-stranded cDNAs: a new tool for cloning 5' ends of mRNAs and for 
constructing cDNA libraries by in vitro amplification. Nucleic Acids Res 19, 5227-
5232 
!!
41!
44. Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, 
E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., Wang, S., Ren, P., Martin, M., 
Jessen, K., Feldman, M. E., Weissman, J. S., Shokat, K. M., Rommel, C., and 
Ruggero, D. (2012) The translational landscape of mTOR signalling steers cancer 
initiation and metastasis. Nature 485, 55-61 
45. Huang, B. P., Wang, Y., Wang, X., Wang, Z., and Proud, C. G. (2009) 
Blocking eukaryotic initiation factor 4F complex formation does not inhibit the 
mTORC1-dependent activation of protein synthesis in cardiomyocytes. Am J Physiol 
Heart Circ Physiol 296, H505-514 
46. Schwarzer, M., Osterholt, M., Lunkenbein, A., Schrepper, A., Amorim, P., and 
Doenst, T. (2014) Mitochondrial reactive oxygen species production and respiratory 
complex activity in rats with pressure overload-induced heart failure. J Physiol 592, 
3767-3782 
47. Volkers, M., Toko, H., Doroudgar, S., Din, S., Quijada, P., Joyo, A. Y., 
Ornelas, L., Joyo, E., Thuerauf, D. J., Konstandin, M. H., Gude, N., Glembotski, C. 
C., and Sussman, M. A. (2013) Pathological hypertrophy amelioration by PRAS40-
mediated inhibition of mTORC1. Proc Natl Acad Sci U S A 110, 12661-12666 
48. Gallego-Delgado, J., Lazaro, A., Osende, J. I., Barderas, M. G., Duran, M. C., 
Vivanco, F., and Egido, J. (2006) Comparison of the protein profile of established 
and regressed hypertension-induced left ventricular hypertrophy. J Proteome Res 5, 
404-413 
49. Buttrick, P. M., Schaible, T. F., Malhotra, A., Mattioli, S., and Scheuer, J. 
(1987) Effects of pregnancy on cardiac function and myosin enzymology in the rat. 
Am J Physiol 252, H846-850 
50. Bassien-Capsa, V., Fouron, J. C., Comte, B., and Chorvatova, A. (2006) 
Structural, functional and metabolic remodeling of rat left ventricular myocytes in 
normal and in sodium-supplemented pregnancy. Cardiovasc Res 69, 423-431 
51. Rees, M. L., Subramaniam, J., Li, Y., Hamilton, D. J., Frazier, O. H., and 
Taegtmeyer, H. (2015) A PKM2 signature in the failing heart. Biochem Biophys Res 
Commun 459, 430-436 
52. Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., 
and Blenis, J. (2002) Tuberous sclerosis complex-1 and -2 gene products function 
together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream 
signaling. Proc Natl Acad Sci U S A 99, 13571-13576 
53. Kenney, J. W., Genheden, M., Moon, K. M., Wang, X., Foster, L. J., and 
Proud, C. G. (2016) Eukaryotic elongation factor 2 kinase regulates the synthesis of 
microtubule-related proteins in neurons. J Neurochem 136, 276-284 
!!
42!
54. Lindsey, M. L., Goshorn, D. K., Comte-Walters, S., Hendrick, J. W., Hapke, 
E., Zile, M. R., and Schey, K. (2006) A multidimensional proteomic approach to 
identify hypertrophy-associated proteins. Proteomics 6, 2225-2235 
55. Wong, N., Ojo, D., Yan, J., and Tang, D. (2015) PKM2 contributes to cancer 
metabolism. Cancer Lett 356, 184-191 
56. Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., 
Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., and Cantley, L. C. (2008) 
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and 
tumour growth. Nature 452, 230-233 
57. Yang, W., and Lu, Z. (2015) Pyruvate kinase M2 at a glance. J Cell Sci 128, 
1655-1660 
58. Warburg, O. (1956) On the origin of cancer cells. Science 123, 309-314 
59. Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., and Hu, X. (2011) Shikonin 
and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2. 
Oncogene 30, 4297-4306 
60. Andujar, I., Rios, J. L., Giner, R. M., and Recio, M. C. (2013) Pharmacological 
properties of shikonin - a review of literature since 2002. Planta Med 79, 1685-1697 
61. Allard, M. F., Schonekess, B. O., Henning, S. L., English, D. R., and 
Lopaschuk, G. D. (1994) Contribution of oxidative metabolism and glycolysis to ATP 
production in hypertrophied hearts. Am J Physiol 267, H742-750 
62. Lopaschuk, G. D., Ussher, J. R., Folmes, C. D., Jaswal, J. S., and Stanley, W. 
C. (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90, 
207-258 
63. Stanley, W. C., Recchia, F. A., and Lopaschuk, G. D. (2005) Myocardial 
substrate metabolism in the normal and failing heart. Physiol Rev 85, 1093-1129 
64. Sack, M. N., Rader, T. A., Park, S., Bastin, J., McCune, S. A., and Kelly, D. P. 
(1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing 
heart. Circulation 94, 2837-2842 
65. Abel, E. D., and Doenst, T. (2011) Mitochondrial adaptations to physiological 
vs. pathological cardiac hypertrophy. Cardiovasc Res 90, 234-242 
66. West, J. A., Beqqali, A., Ament, Z., Elliott, P., Pinto, Y. M., Arbustini, E., and 
Griffin, J. L. (2016) A targeted metabolomics assay for cardiac metabolism and 
demonstration using a mouse model of dilated cardiomyopathy. Metabolomics 12, 59 
67. Lahey, R., Wang, X., Carley, A. N., and Lewandowski, E. D. (2014) Dietary fat 
supply to failing hearts determines dynamic lipid signaling for nuclear receptor 
activation and oxidation of stored triglyceride. Circulation 130, 1790-1799 
68. Schroder, R., and Schoser, B. (2009) Myofibrillar myopathies: a clinical and 
myopathological guide. Brain Pathol 19, 483-492 
!!
43!
69. Vasile, V. C., Will, M. L., Ommen, S. R., Edwards, W. D., Olson, T. M., and 
Ackerman, M. J. (2006) Identification of a metavinculin missense mutation, R975W, 
associated with both hypertrophic and dilated cardiomyopathy. Mol Genet Metab 87, 
169-174 
70. Vasile, V. C., Ommen, S. R., Edwards, W. D., and Ackerman, M. J. (2006) A 
missense mutation in a ubiquitously expressed protein, vinculin, confers 
susceptibility to hypertrophic cardiomyopathy. Biochem Biophys Res Commun 345, 
998-1003 
71. Sharp, W. W., Simpson, D. G., Borg, T. K., Samarel, A. M., and Terracio, L. 
(1997) Mechanical forces regulate focal adhesion and costamere assembly in 
cardiac myocytes. Am J Physiol 273, H546-556 
72. Arber, S., Hunter, J. J., Ross, J., Jr., Hongo, M., Sansig, G., Borg, J., Perriard, 
J. C., Chien, K. R., and Caroni, P. (1997) MLP-deficient mice exhibit a disruption of 
cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 
88, 393-403 
73. Vafiadaki, E., Arvanitis, D. A., Papalouka, V., Terzis, G., Roumeliotis, T. I., 
Spengos, K., Garbis, S. D., Manta, P., Kranias, E. G., and Sanoudou, D. (2014) 
Muscle lim protein isoform negatively regulates striated muscle actin dynamics and 
differentiation. FEBS J 281, 3261-3279 
74. Sussman, M. A., Welch, S., Cambon, N., Klevitsky, R., Hewett, T. E., Price, 
R., Witt, S. A., and Kimball, T. R. (1998) Myofibril degeneration caused by 
tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin 
Invest 101, 51-61 
75. Lu, S., Crawford, G. L., Dore, J., Anderson, S. A., Despres, D., and Horowits, 
R. (2011) Cardiac-specific NRAP overexpression causes right ventricular dysfunction 
in mice. Exp Cell Res 317, 1226-1237 
76. Chereau, D., Boczkowska, M., Skwarek-Maruszewska, A., Fujiwara, I., 
Hayes, D. B., Rebowski, G., Lappalainen, P., Pollard, T. D., and Dominguez, R. 
(2008) Leiomodin is an actin filament nucleator in muscle cells. Science 320, 239-
243 
77. Wang, L., and Proud, C. G. (2002) Regulation of the phosphorylation of 
elongation factor 2 by MEK-dependent signalling in adult rat cardiomyocytes. FEBS 
Lett 531, 285-289 
 
  
!!
44!
FIGURE LEGENDS 
Figure 1. Scheme of method combining pSILAC with AHA labeling. See 
EXPERIMENTAL PROCEDURES for further information. 
 
Figure 2. Optimization of pSILAC conditions. (A) ARVC and HEK293 cells were 
maintained as described in methods; 30 min prior to adding [35S]methionine. DMEM 
was replaced by M199 medium and some cells were treated with cycloheximide (35.54 
µmol/L) where indicated. 18 h later, cells were lysed and analysed for [35S]methionine 
incorporation as described in the Methods. (B) Twelve different tissues from a single rat 
were pulverised in liquid nitrogen, then lysed with RIPA buffer. Protein concentrations were 
measured by the BCA method and 20 µg of protein from each were subject to western blots. 
(C) HeLa cells and ARVC were labeled with AHA for 18 h. Cells were then lysed, and 
subjected to the ‘click’ reaction, the alkyne carrier being alkyne-agarose resin. 
Corresponding amounts of input lysate and supernatant after click reaction were clicked to 
alkyne-biotin and visualized by Streptavidin, Alexa Fluor® 680. (D) ARVC were pre-
incubated in M199 medium with different concentrations of methionine (25% = 25.13 µmol/L, 
50% = 50.26 µmol/L) for 30 min, AHA or normal methionine were then added into the 
medium immediately after treatment, After different time periods as indicated, cells were 
lysed, the same amount of total proteins from each group were subjected to click reaction. 
The alkyne carrier here is biotin-alkyne. After Click reaction, 40 µl of reaction product were 
analysed by SDS-PAGE followed by Streptavidin, Alexa Fluor® 680 visualization. The bar 
graph shows quantification for newly-synthesized protein minus negative control (lane 3) (E) 
ARVC were incubated in M199 medium with low concentration of methionine (25.13 µmol/L) 
for 30 min. Some were then stimulated by insulin or PE as indicated and [35S]methionine 
was added to the medium immediately. 48 h later, cells were lysed and 20 µg of total protein 
were subjected to SDS-PAGE and Coomassie blue staining, while newly-synthesized 
proteins in the dried gel were visualized by autoradiography. The bar graph shows 
quantification for newly-synthesized protein:total protein from three independent experiments. 
Significance was determined by Student’s t-test. 
 
Figure 3. Hierarchical clustering analysis in heat map format of analysed proteins. (A) 
Insulin and PE increase the synthesis of a range of proteins via the mTORC1 pathway, as 
their synthesis is inhibited by rapamycin. The molecular function gene ontology of these 
proteins were manually curated with ExPASy bioinformatics resource portal 
(http://www.expasy.org) and mapped to glycolysis, energy and metabolism, fatty acids beta-
oxidation, amino acid metabolism, ATP synthesis, translation factors, 
cytoskeleton/sarcomere proteins, heat shock proteins or other/unclassified proteins. (B) The 
ten proteins whose synthesis is increased most strongly by insulin in comparison to PE. The 
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data are plotted as (change in synthesis caused by insulin- change caused by PE)/change 
caused by PE as a percentage.  
 
Figure 4. (A) Direct Protein Interaction Network (PIN) in silico analysis of all differentially 
expressed proteins after insulin and PE activation (B) PIN in silico analysis of all differentially 
expressed proteins after insulin + rapamycin and PE + rapamycin activation. PIN analysis 
was performed with MetaCore and curated with DAVID gene ontologies of subcellular 
localization. The analysed proteins are color-coded as red and blue, indicating their up- or 
down regulation, respectively. The red, blue and grey lines denote a positive, negative or 
unspecified regulation, respectively. 
 
Figure 5. Validation of pSILAC results in ARVC. (A) ARVC were starved in M199 medium 
containing low methionine (25.13 µmol/L) for 30 min. Cells were then stimulated with insulin 
or PE as indicated. [35S]methionine was added into the medium immediately after treatment 
and, 48 h later, cells were lysed and HSP60 was IP’d from 250 µg total lysate. IPs were 
subjected to SDS-PAGE and Coomassie brilliant blue staining, while newly-synthesized 
HSP60 in the dried gel was visualized by autoradiography. (B) ARVC were treated and lysed 
as in panel A. Endogenous ACO2 was then IP’d from 250 µg of cell lysate. IP’s were divided 
into two equal portions; one was analysed by western blot to verify the IP efficiency, while 
the other was used for verification of pSILAC result by Click reaction as described in 
Methods. (C) ARVC were isolated and maintained as described in Methods. Cells were 
transferred to low-methionine medium (25.13 µmol/L) 30 min prior to treatment. ARVC were 
treated with PE or insulin where indicated. Normal methionine or AHA was added into the 
medium immediately after treatment; 48 h later, cells were lysed and the same amounts of 
total protein were subjected to western blots. (D) ARVC were isolated, maintained and 
treated as in panel C, 48 h later, cells were lysed, total RNA was extracted and subjected to 
RT-qPCR for the Aco2, Hspd1, Mb, Desmin, and Acadl mRNAs. (E) Summary depiction of 
changes in protein synthesis rates and mRNA levels of selected candidate genes. (F) 5’-
UTRs of the Desmin, Aldoa, and Jup mRNAs. 
 
Figure 6. Expression of PKM2 and eEF1G is upregulated in TAC animal model. (A, B) 
TAC operation was as described in EXPERIMENTAL PROCEDURES. At two- and six-week 
time points, six experimental rats and six age-paired controls were sacrificed; left ventricles 
were pulverised in liquid nitrogen, then lysed with RIPA buffer, and protein concentration 
was measured by the BCA method. 20 µg of protein from each heart was subjected to 
western blots. (C) Quantification of PKM2 and eEF1G from panels A, B. (D, E) Control and 
!!
46!
TAC rats were as described in panel A (six in each group). At two- and six-week time points, 
six experimental rats and six age-paired controls were sacrificed. Total RNA was extracted 
from the left ventricles by TRIzol and analysed by RT-qPCR.  
 
Figure 7. Chronic activation of mTORC1 in MEFs increases the expression of JUP, 
ADLOA, ACO2, and MDH2 proteins. Wild-type and TSC2-/- MEFs were cultured in 
complete DMEM. (A) After lysis, 20 µg of total protein were subjected to western blot using 
the indicated antibodies. (B) After lysis, total RNA was extracted and subjected to RT-qPCR 
analysis for Mdh2, Jup, Aco2, Aldoa, Hspd1, and Rps6. (C) Quantification and summary 
table of panels A and B. 
 
Figure 8. Metabolic remodelling model reflected in the distinct patterns of protein synthesis 
induced by the PE and Insulin in cardiomyocytes, (see Discussion for details). 
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